All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubGVhD HubLymphoma HubMDS HubMultiple Myeloma Hub
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert Opinions

Dual targeting of JAK2 and ERK1/2 enhances clone control and therapeutic efficacy in MPN

The activation of JAK2 signaling triggers the overproduction of mature blood cells of the myeloid lineage, ultimately leading to myeloproliferative neoplasms...

Oct 18, 2021
|MPN
Jean-Jacques Kiladjian

"In the MPN Hub, we have gathered the most recent and most relevant information about MPN pathophysiology, clinical advances, and therapy. You are sure to find a response to your burning questions about MPN here!"

Featured Expert Opinion

Polycythemia vera

view more

Primary myelofibrosis

view more

Most Read

JAK2 driver mutations

view more

Most Viewed